Synthesis and evaluation of 18F-labeled carbonic anhydrase IX inhibitors for imaging with positron emission tomography

Journal of Enzyme Inhibition and Medicinal Chemistry

Volumn 29, Issue 2, 2014, Pages 249-255

  Pan, Jinhe ^a   Lau, Joseph ^a   Mesak, Felix ^a   Hundal, Navjit ^a   Pourghiasian, Maral ^a   Liu, Zhibo ^b   Bénard, François ^a   Dedhar, Shoukat ^a   Supuran, Claudiu T ^c   Lin, Kuo Shyan ^a  

^a BRITISH COLUMBIA CANCER AGENCY   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c UNIVERSITY OF FLORENCE   (Italy)

Author keywords

Benzenesulfonamide; Coumarin; Cytochrome P450

Indexed keywords

7 (2 FLUOROETHOXY)COUMARIN F 18; CARBONATE DEHYDRATASE INHIBITOR; CARBONATE DEHYDRATASE IX; TRACER; U 104 F 18; UNCLASSIFIED DRUG; CA9 PROTEIN, HUMAN; CARBONATE DEHYDRATASE; FLUORINE; INTERLEUKIN 2 RECEPTOR; RADIOPHARMACEUTICAL AGENT; TUMOR ANTIGEN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; DRUG DISTRIBUTION; DRUG METABOLISM; DRUG STABILITY; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG UPTAKE; ENZYME INHIBITION; IMMUNOHISTOCHEMISTRY; ISOTOPE LABELING; MOUSE; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN EXPRESSION; RADIOACTIVITY; ADENOCARCINOMA; ANIMAL; CHEMICAL STRUCTURE; CHEMISTRY; DRUG SCREENING; GENETICS; HT 29 CELL LINE; HUMAN; KNOCKOUT MOUSE; METABOLISM; METHODOLOGY; NONOBESE DIABETIC MOUSE; SCID MOUSE; SCINTISCANNING; SYNTHESIS; TISSUE DISTRIBUTION;

ADENOCARCINOMA; ANIMALS; ANTIGENS, NEOPLASM; CARBONIC ANHYDRASE INHIBITORS; CARBONIC ANHYDRASES; DRUG STABILITY; FLUORINE RADIOISOTOPES; HT29 CELLS; HUMANS; MICE; MICE, INBRED NOD; MICE, KNOCKOUT; MICE, SCID; MOLECULAR STRUCTURE; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; RECEPTORS, INTERLEUKIN-2; TISSUE DISTRIBUTION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84896355347     PISSN: 14756366     EISSN: 14756374     Source Type: Journal    
DOI: 10.3109/14756366.2013.773994     Document Type: Article

References (49)

1. Supuran CT. Carbonic anhydrases: novel therapeutic applications for inhibitors and activators. Nat Rev Drug Discov 2008;7:168-81.
2. Oosterwijk E, Ruiter DJ, Hoedemaeker PJ, et al. Monoclonal antibody G-250 recognizes a determinant present in renal-cell carcinoma and absent from normal kidney. Int J Cancer 1986;38: 489-94.
3. Ord JJ, Agrawal S, Thamboo TP, et al. An investigation into the prognostic significance of necrosis and hypoxia in high grade and invasive bladder cancer. J Urol 2007;178:677-82.
4. Hutchison GJ, Valentine HR, Loncaster JA, et al. Hypoxia-inducible factor lot expression as an intrinsic marker of hypoxia: Correlation with tumor oxygen, pimonidazole measurements, and outcome in locally advanced carcinoma of the cervix. Clin Cancer Res 2004;10: 8405-12.
5. Koukourakis MI, Bentzen SM, Giatromanolaki A, et al. Endogenous markers of two separate, hypoxia response pathways (hypoxia inducible factor 2 alpha and carbonic anhydrase 9) are associated with radiotherapy failure in head and neck cancer patients recruited in the CHART randomized trial. J Clin Oncol 2006;24:727-35.
6. Trastour C, Benizri E, Ettore F, et al. HIF-1 alpha and CA IX staining in invasive breast carcinomas: prognosis and treatment outcome. Int J Cancer 2007;120:1451-8.
7. Hussain SA, Ganesan R, Reynolds G, et al. Hypoxia-regulated carbonic anhydrase IX expression is associated with poor survival in patients with invasive breast cancer. Brit J Cancer 2007;96:104-9.
8. Swinson DEB, Jones JL, Richardson D, et al. Carbonic anhydrase IX expression, a novel surrogate marker of tumor hypoxia, is associated with a poor prognosis in non-small-cell lung cancer. J Clin Oncol 2003;21:473-82.
9. Dorai T, Sawczuk I, Pastorek J, et al. Role of carbonic anhydrases in the progression of renal cell carcinoma subtypes: proposal of a unified hypothesis. Cancer Invest 2006;24:754-79.
10. Wykoff CC, Beasley NJP, Watson PH, et al. Hypoxia-inducible expression of tumor-associated carbonic anhydrases. Cancer Res 2000;60:7075-83.
11. Mandriota SJ, Turner KJ, Davies DR, et al. HIF activation identifies early lesions in VHL kidneys: evidence for site-specific tumor suppressor function in the nephron. Cancer Cell 2002;1:459-68.
12. Ivanov SV, Kuzmin I, Wei MH, et al. Down-regulation of transmembrane carbonic anhydrases in renal cell carcinoma cell lines by wild-type von Hippel-Lindau transgenes. Proc Natl Acad Sci USA 1998;95:12596-601.
13. Lou Y, McDonald PC, Oloumi A, et al. Targeting tumor hypoxia: suppression of breast tumor growth and metastasis by novel carbonic anhydrase IX inhibitors. Cancer Res 2011;71:3364-76.
14. Korkeila E, Talvinen K, Jaakkola PM, et al. Expression of carbonic anhydrase IX suggests poor outcome in rectal cancer. Brit J Cancer 2009;100:874-80.
15. Koukourakis MI, Giatromanolaki A, Sivridis E, et al. Hypoxiaactivated tumor pathways of angiogenesis and pH regulation independent of anemia in head-and-neck cancer. Int J Radiat Oncol Biol Phys 2004;59:67-71.
16. Swietach P, Hulikova A, Vaughan-Jones RD, Harris AL. New insights into the physiological role of carbonic anhydrase IX in tumour pH regulation. Oncogene 2010;29:6509-21.
17. Svastova E, Hulikova A, Rafajova M, et al. Hypoxia activates the capacity of tumor-associated carbonic anhydrase IX to acidify extracellular pH. FEBS Lett 2004;577:439-45.
18. Swietach P, Vaughan-Jones RD, Harris AL. Regulation of tumor pH and the role of carbonic anhydrase 9. Cancer Metast Rev 2007;26: 299-310.
19. Kroemer G, Pouyssegur J. Tumor cell metabolism: ancer's achilles' heel. Cancer cell 2008;13:472-82.
20. Stock C, Schwab A. Protons make tumor cells move like clockwork. Pflug Arch Eur J Physiol 2009;458:981-92.
21. Supuran CT. Indisulam: an anticancer sulfonamide in clinical development. Expert Opin Investig Drugs 2003;12:283-7.
22. Thiry A, Dogne JM, Masereel B, Supuran CT. Targeting tumorassociated carbonic anhydrase IX in cancer therapy. Trends Pharmacol Sci 2006;27:566-73.
23. Siebels M, Rohrmann K, Oberneder R, et al. A clinical phase I/II trial with the monoclonal antibody cG250 (RENCAREX®) and interferon-alpha-2a in metastatic renal cell carcinoma patients. World J Urol 2011;29:121-6.
24. Belldegrun A. Chimeric monoclonal antibody cG250 (Rencarex®) as immunotherapy of renal cell carcinoma: clinical Phase II summary and current adjuvant Phase III trial in non-metastasized RCC after nephrectomy. Ann Oncol 2005;16:18.
25. Stillebroer AB, Mulders PFA, Boerman OC, et al. Carbonic anhydrase IX in renal cell carcinoma: implications for prognosis, diagnosis, and therapy. Eur Urol 2010;58:75-83.
26. Brouwers AH, Dorr U, Lang O, et al. 131I-cG250 monoclonal antibody immunoscintigraphy versus [18F]FDG-PET imaging in patients with metastatic renal cell carcinoma: a comparative study. Nucl Med Commun 2002;23:229-36.
27. Brouwers AH, Buijs WC, Boerman OC, et al. Higher uptake in renal cell carcinoma (RCC) metastases with In-111-labeled chimeric monoclonal antibody G250 (cG250) than with I-131-cG250 in an intra-patient comparison. J Nucl Med 2003;44:171P-2P.
28. Divgi CR, Pandit-Taskar N, Jungbluth AA, et al. Preoperative characterisation of clear-cell renal carcinoma using iodine-124- labelled antibody chimeric G250 (124I-cG250) and PET in patients with renal masses: a phase I trial. Lancet Oncol 2007;8:304-10.
29. Hoeben BAW, Kaanders JHAM, Franssen GM, et al. PET of hypoxia with 89Zr-Labeled cG250-F(ab0)2 in head and neck tumors. J Nucl Med 2010;51:1076-83.
30. Apte SD, Chin FT, Graves EE. Synthesis of a new PET radiotracer targeting carbonic anhydrase IX. J Label Compd Radiopharm 2009; 52:S408.
31. Akurathi V, Dubois L, Lieuwes NG, et al. Synthesis and biological evaluation of a 99mTc-labelled sulfonamide conjugate for in vivo visualization of carbonic anhydrase IX expression in tumor hypoxia. Nucl Med Biol 2010;37:557-64.
32. Asakawa C, Ogawa M, Kumata K, et al. Radiosynthesis of three [11C]ureido-substituted benzenesulfonamides as PET probes for carbonic anhydrase IX in tumors. Bioorg Med Chem Lett 2011;21: 7017-20.
33. Kolb HC, Walsh JC, Kasi D, et al. Development of molecular imaging probes for carbonic anhydrase-IX using click chemistry. US Patent 0317842; 2010.
34. Doss M, Alpaugh RK, Yu JQ. Biodistribution and radiation dosimetry of CA-IX PET imaging agent 18F-VM4-037 measured in healthy volunteers. Mol Imaging Biol 2010;12:S124.
35. Lu G, Hillier SM, Maresca KP, et al. Synthesis and SAR of novel Re/99mTc-labeled benzenesulfonamide carbonic anhydride IX inhibitors for molecular imaging of tumor hypoxia. J Med Chem 2013;56:510-20.
36. Pacchiano F, Carta F, McDonald PC, et al. Ureido-substituted benzenesulfonamides potently inhibit carbonic anhydrase IX and show antimetastatic activity in a model of breast cancer metastasis. J Med Chem 2011;54:1896-902.
37. Baker BR, Hurlbut JA. Irreversible enzyme inhibitors. CLIIIProteolytic enzymes 11 Inhibition of guinea pig complement by substituted phenoxyacetamides. J Med Chem 1969;12:415-19.
38. Carta F, Maresca A, Scozzafava A, Supuran CT. Novel coumarins and 2-thioxo-coumarins as inhibitors of the tumor-associated carbonic anhydrases IX and XII. Bioorg Med Chem 2012;20: 2266-73.
39. Touisni N, Maresca A, McDonald PC, et al. Glycosyl coumarin carbonic anhydrase IX and XII inhibitors strongly attenuate the growth of primary breast tumors. J Med Chem 2011;54:8271-7.
40. Wilson AA, Dasilva JN, Houle S. Synthesis of two radiofluorinated cocaine analogs using distilled 2-[18F]fluoroethyl bromide. Appl Radiat Isot 1995;46:765-70.
41. Gokce B, Gencer N, Arslan O, et al. Evaluation of in vitro effects of some analgesic drugs on erythrocyte and recombinant carbonic anhydrase I and II. J Enzym Inhib Med Chem 2012;27:37-42.
42. Senturk M, Gulcin I, Beydemir S, et al. In vitro inhibition of human carbonic anhydrase I and II isozymes with natural phenolic compounds. Chem Biol Drug Des 2011;77:494-9.
43. Guler OO, de Simone G, Supuran CT. Drug design studies of the novel antitumor targets carbonic anhydrase IX and XII. Curr Med Chem 2010;17:1516-26.
44. Hendricks JA, Keliher EJ, Marinelli B. In vivo PET imaging of histone deacetylases by 18F-suberoylanilide hydroxamic acid (18F-SAHA). J Med Chem 2011;54:5576-82.
45. Groves K, Bao B, Zhang J, et al. Synthesis and evaluation of nearinfrared fluorescent sulfonamide derivatives for imaging of hypoxiainduced carbonic anhydrase IX expression in tumors. Bioorg Med Chem Lett 2012;22:653-7.
46. Kim KH, Isin EM, Yun CH, et al. Kinetic deuterium isotope effects for 7-alkoxycoumarin O-dealkylation reactions catalyzed by human cytochromes P450 and in liver microsomes - rate-limiting C-H bond breaking in cytochrome P450 1A2 substrate oxidation. FEBS J 2006;273:2223-31.
47. Yamazaki H, Inoue K, Mimura M, et al. 7-ethoxycoumarin O-deethylation catalyzed by cytochromes P450 1A2 and 2E1 in human liver microsomes. Biochem Pharmacol 1996;51:313-19.
48. Tewson TJ, Welch MJ. Preparation and preliminary biodistribution of no carrier added F-18 fluoroethanol. J Nucl Med 1980;21: 559-64.
49. Ling G, Gu J, Genter MB, et al. Regulation of cytochrome P450 gene expression in the olfactory mucosa. Chem Biol Interact 2004; 147:247-58.